Retrospective, Non-interventional, Comparative Clinical Investigation of the Safety and Performance of 690AD and 690ADY Monofocal Intraocular Lens Implantation With Extended Patient Enrolment
Key facts
- Who runs it
- Medicontur Medical Engineering Ltd
- Where
- Hungary2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 51 people enrolled
- Started
- 15 Jan 2024
- Ended
- 3 May 2024
- Type of study
- Observational, 2 groups
- Treatments tested
- Standard of care
- Patient satisfaction questionnare
- Record updated
- 30 August 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
Show the full registry criteria (8)Hide the full registry criteria
Who can take part
- Adult males or females above 18 years of age
- Pseudophakic patients implanted with 690AD or 690ADY monofocal IOLs (implanted between June 2022 - September 2023)
- Diagnosis of cataract and/or ametropia (hyperopia, myopia)
- Subject who has signed an informed consent form
- Patients who have participated in all visits that are subject to retrospective data collection
Who cannot take part
- Patients with the following condition(s) at the time of the baseline visit:; Corneal astigmatism > 1.0D; Uncontrolled diabetic retinopathy; Iris neovascularization; Congenital eye abnormality; Uncontrolled glaucoma; Pseudoexfoliation syndrome; Amblyopia; Uveitis; AMD (advanced AMD); Retinal detachment; Prior ocular surgery in personal medical history; Previous laser treatment; Corneal diseases; Severe retinal diseases (dystrophy, degeneration); High myopia; Inadequate visualization of the fundus on preoperative examination; Patients deemed by the clinical investigator because of any systemic disease; Pregnancy; Eye trauma in medical history; Current use of systemic steroids or topical ocular medication
- Patients with any eye condition that could affect vision in the opinion of the investigator at the time of the 12-month follow-up: (corneal ectasia, retinal diseases, glaucoma, uveitis, dry eye or amblyopia, etc.)
- Patients who are not targeted to emmetropia
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Medicontur hydrophilic posterior chamber monofocal intraocular lens (IOLs) are indicated to improve vision at far distance in adults with cataract and/or ametropia (hyperopia, myopia), secondarily to removal of the crystalline lens.
Read full original descriptionShow less
The intraocular lens is intended to be surgically implanted into the eye with the purpose of restoring optical function in the aphakic eye to provide an optical system with high predictability of the precalculated dioptric power.
The study will be performed partially as a retrospective study with patients enrolled who had been implanted with 690AD or 690ADY IOLs mono- or binocularly between June 2022 - September 2023.
Data from five visits will be collected:
* Baseline preoperative (maximum 90 days prior to surgery)- retrospective * IOL implantation Day 0 - retrospective * Postoperative visit at Day 1 (+/- 0 days) - retrospective * Postoperative visit at 1 month (+/- 2 weeks) - retrospective * Postoperative visit at 12 months (+/- 3 months) - consent and prospective visit
The 2 groups in the trial
- 690AD
35 eyes /patients implanted with 690AD IOL
Treatment: Standard of care and Patient satisfaction questionnare
- 690ADY
35 eyes /patients implanted with 690ADY IOL
Treatment: Standard of care and Patient satisfaction questionnare
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 30 August 2024